Ketjussa niin paljon viestintää, että en tiedä onko DNB Carnegien osarikommentit olleet linkattuna. Varsinainen 10-sivuinen pdf on ao linkin takana
Summary:
Expenses declined more than we expected in H2 versus H1 2025, reflecting lower clinical activity. Plans for the lead asset, bexmarilimab (BEX), remain intact, with Faron focused on generating additional data in solid tumours through investigator-led trials while independently advancing the high-risk MDS programme. Pending further clarity on the planned financing, we maintain our fair value range of EUR1.0–1.8.
DNB Carnegie Access: Financing terms remain in focus - H2 review DNB Carnegie Access: